Blood and Lymphatic Cancer-Targets and Therapy最新文献_第5页

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions 阴燃型多发性骨髓瘤:患病率和指导治疗决策的现有证据

IF 2.8

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2018-04-20 DOI: 10.2147/BLCTT.S136447

Agnieszka Blum, D. Bazou, P. O’gorman

引用次数: 9

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era 正电子发射断层扫描时代晚期霍奇金淋巴瘤化疗后的结果和复发模式

IF 2.8

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2018-04-18 DOI: 10.2147/BLCTT.S160404

C. Lapuz, A. Enjeti, P. O'Brien, A. Capp, E. Holliday, S. Gupta

{"title":"Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era","authors":"C. Lapuz, A. Enjeti, P. O'Brien, A. Capp, E. Holliday, S. Gupta","doi":"10.2147/BLCTT.S160404","DOIUrl":"https://doi.org/10.2147/BLCTT.S160404","url":null,"abstract":"Background This study evaluated relapse patterns and survival in advanced Hodgkin lymphoma (HL) patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) with positron emission tomography (PET) used for staging and response assessment. Patients and methods Patients aged 18 years or above with newly diagnosed histologically proven Stage III or IV HL treated with ABVD at Calvary Mater Newcastle from January 2005 to December 2012 were included in this study. All patients underwent pre-chemotherapy staging with 18F-fluorodeoxyglucose PET or PET/computed tomography and post-chemotherapy PET or PET/computed tomography for the assessment of response. Results Forty-three patients were included in the study. The 5-year disease-free survival, progression-free survival and overall survival were 88%, 74% and 86%, respectively. PET complete response was seen in 35 patients (81%), and the 5-year overall survival for this group was 94%. Relapse following a PET complete response was low (three patients) and occurred predominantly at the initial sites of disease. Four of five patients with bulky disease received consolidative radiotherapy and no in-field relapses were observed. Conclusion Advanced stage HL with a PET complete response following ABVD is associated with an excellent prognosis.","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2018-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85489531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives. 聚焦治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的泊纳替尼：患者选择与展望。

IF 3.9

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-12-22 eCollection Date: 2018-01-01 DOI: 10.2147/BLCTT.S130197

Theodora Anagnostou, Mark R Litzow

{"title":"Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives.","authors":"Theodora Anagnostou, Mark R Litzow","doi":"10.2147/BLCTT.S130197","DOIUrl":"10.2147/BLCTT.S130197","url":null,"abstract":"Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute lymphoblastic leukemia that are either resistant or unable to tolerate another tyrosine kinase inhibitor. Its US Food and Drug Administration approval was based on results from long-term follow-up of the pivotal Phase II PACE trial, which demonstrated deep and durable molecular responses in the treated patients. Despite the remarkable responses, ponatinib has been associated with high frequency of severe vascular events, which led to its withdrawal from the market in 2013. Following analysis of the risk factors of patients who developed vascular side effects, ponatinib was reintroduced in the market 1 year later with specific dose-reduction recommendations and carrying a black box warning. Thus, careful patient selection with identification of patients whose potential benefit from ponatinib exceeds the potential risks associated with its use is crucial. Ongoing and future studies are focusing on earlier detection of mutations, strategies to minimize side effects, and potential expansion of the treatment indications. Clinical trials testing the safety and efficacy of ponatinib as frontline therapy are ongoing.","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2017-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89279550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects 母浆细胞样树突状细胞肿瘤:挑战与未来展望

IF 2.8

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-12-11 DOI: 10.2147/BLCTT.S132060

A. Trottier, S. Cerquozzi, C. Owen

引用次数: 9

Impact of obinutuzumab alone and in combination for follicular lymphoma 单抗和联合用药对滤泡性淋巴瘤的影响

IF 2.8

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-10-19 DOI: 10.2147/BLCTT.S114173

M. Sarraf Yazdy, B. Cheson

{"title":"Impact of obinutuzumab alone and in combination for follicular lymphoma","authors":"M. Sarraf Yazdy, B. Cheson","doi":"10.2147/BLCTT.S114173","DOIUrl":"https://doi.org/10.2147/BLCTT.S114173","url":null,"abstract":"Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory setting, but also for initial treatment. Obinutuzumab (G, GA101) is a third-generation, fully humanized type II glycoengineered, anti-CD20 monoclonal antibody that results in increased direct cell death and antibody-dependent, cell-mediated cytotoxicity/phagocytosis compared to rituximab. Obinutuzumab has significant antitumor activity when used alone or in combinations in untreated or relapsed refractory FL patients. Studies have demonstrated its ability to prolong progression-free survival and, in some cases, overall survival, and to eliminate minimal residual disease. Several ongoing trials are investigating combinations with chemotherapy, immunomodulators, targeted drugs, and immunotherapy agents. G is generally well tolerated, with associated adverse effects including infusion-related reactions, neutropenia, thrombocytopenia, and reactivation of hepatitis B virus. Future studies with this antibody should focus on identifying predictive markers and developing chemotherapy-free combinations that will improve the outcome of patients with FL.","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87358642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Complications and management of coagulation disorders in leukemia patients. 白血病患者凝血功能障碍的并发症和处理方法。

IF 3.9

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-09-18 eCollection Date: 2017-01-01 DOI: 10.2147/BLCTT.S125121

Deepesh Lad, Arihant Jain, Subhash Varma

引用次数: 0

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma 卡非佐米在复发性多发性骨髓瘤二线及以上治疗中的应用

IF 2.8

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-07-19 DOI: 10.2147/BLCTT.S82444

D. Bhutani, J. Zonder

引用次数: 0

Clinical potential of midostaurin in advanced systemic mastocytosis midoin治疗晚期全身肥大细胞增多症的临床潜力

IF 2.8

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-05-03 DOI: 10.2147/BLCTT.S87186

M. Chandesris, G. Damaj, O. Lortholary, O. Hermine

{"title":"Clinical potential of midostaurin in advanced systemic mastocytosis","authors":"M. Chandesris, G. Damaj, O. Lortholary, O. Hermine","doi":"10.2147/BLCTT.S87186","DOIUrl":"https://doi.org/10.2147/BLCTT.S87186","url":null,"abstract":"Advanced (Ad) systemic mastocytoses (SM) include aggressive SM (ASM) and mast cell leukemia (MCL) with or without an associated clonal hematological non-mast cell lineage disease (AHNMD). They are rare (<15%) but are associated with a poor prognosis due to rapid organ dysfunction. To date, responses to high-dose chemotherapy, cladribine, and imatinib were revealed to be suboptimal with a median survival time of 24 months. Midostaurin is a potent multikinase inhibitor including the most frequent KIT D816V mutation (>80%). We herein present a review of the most recent data of the use of midostaurin in AdSM. First, a multicenter Phase II study (CPKC412D2213) revealed an unprecedented overall response rate (ORR) of 69% regardless of KIT mutational status, with 38% of major response (MR) among 26 AdSM patients treated with midostaurin alone 200 mg daily. Second, a sponsor-initiated, multicenter, single-arm open Phase II study (CPKC412D2201) confirmed a high and durable ORR of 60% including 45% of MR among 89 AdSM patients. Finally, a French compassionate use program managed by the French Reference Centre for Mastocytosis allowed the treatment of almost a hundred AdSM patients to date in France since the CPKC412D2201 study closure. The outcome of the first 28 treated patients under cover of this on-going procedure revealed an ORR of 71% including 57% of MR. Most importantly, survival analysis revealed in comparison to a historical control cohort of AdSM patients who did not receive midostaurin a twofold lower risk of death (p=0.02) in midostaurin-treated patients. Side effects revealed were acceptable and manageable (mostly digestive). Midostaurin appears to be an effective and safe treatment of AdSM. However, its effect on the course of the AHNMD is less clear. For the future, combined therapy (hypomethylating agents, cladribine, mammalian target of rapamycin inhibitors, chemotherapy, and allogeneic bone marrow transplantation) may further improve long-term survival, particularly that of MCL and AdSM patients with AHNMD.","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82955371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uptake of lymphoma-derived exosomes by peripheral blood leukocytes 外周血白细胞对淋巴瘤源性外泌体的摄取

IF 2.8

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-02-28 DOI: 10.2147/BLCTT.S130826

Heather R. Ferguson Bennit, Amber Gonda, L. Oppegard, David P Chi, Salma Khan, N. Wall

{"title":"Uptake of lymphoma-derived exosomes by peripheral blood leukocytes","authors":"Heather R. Ferguson Bennit, Amber Gonda, L. Oppegard, David P Chi, Salma Khan, N. Wall","doi":"10.2147/BLCTT.S130826","DOIUrl":"https://doi.org/10.2147/BLCTT.S130826","url":null,"abstract":"Exosomes are nanosized lipid vesicles secreted into blood and other body fluids and serve as vehicles for intercellular communication. Despite being an important component of the tumor microenvironment (TME), exosomal targeting and uptake into recipient cells are still not fully understood. Few studies have looked at lymphoma exosomes and their interactions with circulating blood cells. In this study, we examine the exosomal uptake distribution among peripheral blood leukocytes (PBLs) using vesicles derived from a diffuse large B cell lymphoma cell line, WSU-DLCL2. Lymphoma cells survive, proliferate, and are protected from the cytotoxic effects of chemotherapeutic agents by soluble factors or by direct contact with inflammatory and stromal cells within the TME. In an attempt to close the gap in knowledge concerning lymphoma TME immunosuppression, we have treated normal human PBLs with PKH67-labeled lymphoma exosomes and monitored the uptake by measuring fluorescence at different time points using flow cytometry and fluorescent microscopy. Our results show that of the four populations examined, B cells and monocytes demonstrated uptake of PKH67-labeled exosomes, while T cells and NK cells displayed significantly less uptake.","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2017-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76483237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma. 霍奇金淋巴瘤治疗中通过程序性死亡1阻断控制免疫系统。

IF 3.9

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2017-02-16 eCollection Date: 2017-01-01 DOI: 10.2147/BLCTT.S110665

Melody B Oncale, Hossein Maymani, Loretta J Nastoupil

{"title":"Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma.","authors":"Melody B Oncale, Hossein Maymani, Loretta J Nastoupil","doi":"10.2147/BLCTT.S110665","DOIUrl":"10.2147/BLCTT.S110665","url":null,"abstract":"Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed to restore the immune system's ability to recognize and destroy cancer cells. Nivolumab and pembrolizumab are two anti-PD-1 antibodies that have demonstrated success in the treatment of refractory Hodgkin lymphoma. Harnessing the immune system's ability to target neoplastic cells, ideally without the use of cytotoxic chemotherapeutic agents, is one way in which these novel agents are changing the therapeutic landscape in the treatment of lymphomas. Here, we review the emerging data regarding checkpoint inhibitors in the management of Hodgkin lymphoma, the unique adverse effects encountered with the use of these agents, and a practical approach to the management of these adverse effects. Additionally, we discuss upcoming trials that will further assess the promising future developments of checkpoint inhibition in the treatment of not only Hodgkin lymphoma but also other B cell lymphomas and myeloma. These agents offer immense promise of a future where many lymphomas can be treated without the toxic effects of chemotherapeutic agents.","PeriodicalId":42368,"journal":{"name":"Blood and Lymphatic Cancer-Targets and Therapy","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2017-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/6e/blctt-7-001.PMC6467338.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41215412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0